🟢 Strong Evidence
A new targeted therapy has achieved a breakthrough in treating pancreatic cancer by successfully inhibiting the KRAS mutation that drives most pancreatic tumors. The drug daraxonrasib nearly doubled survival times for patients with advanced disease and reduced the risk of death by 60% compared to standard chemotherapy, according to results published in The New England Journal of Medicine.
Key takeaways
- Daraxonrasib targets KRAS mutations found in 90% of pancreatic cancers—previously considered “undruggable”
- Median survival increased from 5.7 months with chemotherapy to 11.2 months with the new treatment
- 60% reduction in death risk represents the largest survival improvement in pancreatic cancer in over a decade
Daraxonrasib Shows Superior Survival Outcomes
Median overall survival by treatment group, months
Source: New England Journal of Medicine, 2026 | Georgian Medical Journal News
Targeting the ‘Undruggable’ KRAS Mutation
For over three decades, the KRAS protein has been considered “undruggable” despite being mutated in approximately 90% of pancreatic cancers. The drug represents a new approach to blocking KRAS by targeting what was once thought to be an impossible therapeutic target.
Daraxonrasib works by preventing KRAS from sending growth signals that fuel tumor progression. The FDA granted breakthrough therapy designation to daraxonrasib in 2025 based on early trial results.
Clinical Trial Results Show Dramatic Improvement
In a major clinical trial, daraxonrasib nearly doubled survival for patients with advanced disease. The treatment demonstrated superior outcomes, with significant improvements in both overall survival and disease progression compared to standard treatments.
These findings have particular significance for clinical practice given pancreatic cancer’s historically poor prognosis and limited treatment options.
Implications for Pancreatic Cancer Treatment
These results represent a significant advancement in pancreatic cancer treatment. The success of daraxonrasib validates the concept of targeting KRAS mutations and opens new avenues for treating other KRAS-driven cancers. Research teams are now investigating combinations of KRAS inhibitors with immunotherapy and other targeted agents, as covered in recent medical research updates.
The breakthrough also highlights the potential for precision medicine approaches in pancreatic cancer, where treatment selection based on specific genetic alterations could improve outcomes. The National Cancer Institute has launched several initiatives to expand genetic testing and targeted therapy access for pancreatic cancer patients.
What this means
Frequently asked questions
What makes KRAS mutations so difficult to target?
KRAS proteins have traditionally been challenging to target with drugs, leading many scientists to consider them “undruggable” for decades.
What type of cancer does this target?
This drug targets pancreatic cancers with KRAS mutations, which represent the majority of pancreatic tumors.
How significant is this advancement?
The treatment nearly doubles survival for patients with advanced disease and reduces the risk of death by 60%, representing a major breakthrough in pancreatic cancer treatment.
The development of daraxonrasib marks a pivotal moment in pancreatic cancer treatment, transforming what was once considered an impossible target into a therapeutic reality. As researchers continue to refine KRAS inhibition strategies and explore combination approaches, the outlook for patients with this aggressive disease continues to improve.
Source: Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
